Setting a Goal Weight May Lead to Greater Success With GLP-1s Like Zepbound
Why this matters: health reporting relevant to everyday decisions and well-being.
Setting a weight loss goal may yield greater success with GLP-1 drugs like Zepbound. Image Credit: Crispin la valiente/Getty Images. A recent study found that people who set personal weight loss targets may achieve greater results with GLP-1 medications. People using tirzepatide (Zepbound or Mounjaro) saw more weight loss if they set goals or had previously tried structured diet plans. The results also indicate that women tended to experience greater weight loss with GLP-1s than men, suggesting sex-specific differences. Millions of people have achieved significant weight loss with GLP-1 medications, a blockbuster class of drugs that mimic an appetite-suppressing hormone to trigger significant metabolic changes. Some people may experience more weight loss than others while using these medications, but there are various strategies that can help promote long-term weight loss. New research examined weight loss outcomes among people using tirzepatide (Zepbound and Mounjaro). The study included people who set personal weight loss goals and those without pre-existing conditions, such as type 2 diabetes. The findings show that females lost more weight than males, and those who set personal weight loss goals experienced greater weight loss. The results have not yet been published in a peer-reviewed journal but were presented at ENDO 2026, held from June 13–16 in Chicago, IL. “These findings align with my own clinical experience. I have found that patients who set realistic goals and actively work toward them through dietary and lifestyle changes are more likely to see significant benefits from weight loss medications,” said Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. Ali wasn’t involved in the study. Goal setting yields greater weight loss with GLP-1s The study analyzed data from 80,942 individuals with an average age of 43 who had just begun treatment with a GLP-1 drug containing the active i